|
|
 | | From: | Kofi | | Subject: | Ellagic acid for liver fibrosis | | Date: | Sat, 22 Jan 2005 11:33:22 GMT |
|
|
 | Strange that they don't mention TGF-B1.
Anybody know a purer source for ellagic acid than BAC?
Cell Prolif. 2003 Dec;36(6):307-19. Related Articles, Links
Click here to read
Stages of activation of hepatic stellate cells: effects of ellagic
acid, an inhibiter of liver fibrosis, on their differentiation in
culture.
Buniatian GH.
Max-Planck-Institut fur Zellbiologie, Ladenburg, Germany.
To further explore that hepatic stellate cell (HSC) activation
results in physiological protection against environmental insult, the
profile of differentiation of HSC has been examined upon treatment with
ellagic acid (EA), a plant-derived antioxidant that shows multiple
protective effects during liver disease. Sparse rat liver cell cultures
were grown in media containing EA (3, 6, 30 and 100 microg/ml) and, as
controls, without EA, and inspected until day 7 in culture. The cells
were double-labelled with antibodies against glial fibrillary acidic
protein (GFAP) and smooth muscle alpha-actin (SMAA), marker proteins of
quiescent and activated HSC, respectively. In EA-free culture
conditions, the quiescent (SMAA-/GFAP+) HSC transiently acquired a
semi-activated (SMAA+/GFAP+), phenotype and were further transformed
into activated (SMAA+/GFAP-), pleomorphic HSC. Up to a concentration of
30 microg/ml, EA induced an early synthesis of SMAA in all HSC and
inhibited their morphologic differentiation and individual growth
throughout the culture period. At a concentration of 6 microg/ml, EA
supported the semi-activated (SMAA+/GFAP+) phenotype of HSC throughout
the culture period, whereas treatment with high EA concentrations (30
microg/ml) resulted in an early loss of GFAP expression. In conclusion:
(i) the uniform response of HSC to EA by mild activation adds functional
significance to cellular features preceding the transformation of HSC to
myofibroblasts; (ii) the high sensitivity of HSC to EA treatment
suggests their involvement in any mechanisms of protection by this
antioxidant; (iii) the maintenance of HSC morphology might be one of the
factors playing a role in the prevention or slowing down of liver
fibrosis; (iv) because the effects of EA are concentration- and
time-dependent, an arbitrary usage of this antioxidant is a matter of
potential concern; (v) the various patterns of HSC activation observed
might correspond to distinct activities of these cells, which, in turn,
might lead to different outcomes of liver fibrosis.
PMID: 14710849 [PubMed - indexed for MEDLINE]
|
|
| | From: | John G. | | Subject: | Re: Ellagic acid for liver fibrosis | | Date: | 22 Jan 2005 14:12:14 -0800 |
|
|
| is EA available OTC ?
|
|
| | From: | Kofi | | Subject: | Re: Ellagic acid for liver fibrosis | | Date: | Sun, 23 Jan 2005 04:27:11 GMT |
|
|
| Yes, EA is available OTC. It's in all sorts of fruits.
|
|
|
